Comprehensive Cancer Center, The Ohio State University, 460 W. 10th Avenue, Columbus, OH 43210, USA.
Medical Scientist Training Program, Biomedical Sciences Graduate Program, The Ohio State University, 370 W. 9th Avenue, Columbus, OH 43210, USA.
J Leukoc Biol. 2023 May 2;113(5):518-524. doi: 10.1093/jleuko/qiad026.
Epigenetic therapy is an emerging field in the treatment of human cancer, including hematologic malignancies. This class of therapeutic agents approved by the US Food and Drug Administration for cancer treatment includes DNA hypomethylating agents, histone deacetylase inhibitors, IDH1/2 inhibitors, EZH2 inhibitors, and numerous preclinical targets/agents. Most studies measuring the biological effects of epigenetic therapy focus their attention on either their direct cytotoxic effects on malignant cells or their effects on modifying tumor cell antigen expression, exposing them to immune surveillance mechanisms. However, a growing body of evidence suggests that epigenetic therapy also has effects on the development and function of the immune system, including natural killer cells, which can alter their response to cancer cells. In this review, we summarize the body of literature studying the effects of different classes of epigenetic therapy on the development and/or function of natural killer cells.
表观遗传学治疗是人类癌症治疗领域的一个新兴分支，包括血液系统恶性肿瘤。美国食品和药物管理局批准的这一类治疗癌症的药物包括 DNA 低甲基化剂、组蛋白去乙酰化酶抑制剂、IDH1/2 抑制剂、EZH2 抑制剂以及许多临床前靶点/药物。大多数研究表观遗传学治疗的生物学效应的研究都集中在其对恶性细胞的直接细胞毒性作用或对改变肿瘤细胞抗原表达的作用上，从而使它们暴露于免疫监视机制之下。然而，越来越多的证据表明，表观遗传学治疗也对免疫系统的发育和功能有影响，包括自然杀伤细胞，这可以改变它们对癌细胞的反应。在这篇综述中，我们总结了研究不同类别表观遗传学治疗对自然杀伤细胞的发育和/或功能的影响的文献。
